Vidcast: https://www.instagram.com/p/DMYbs7tJz7Q/

A new so-called “tetra-functional” diet compound has added power and its effects match the weight loss result of bariatric surgery. Chemists at Boston’s Tufts University have engineered a next-generation compound that mimics the action of four different gut hormones involved in appetite control, metabolism, and energy use. They are GLP-1, GIP, glucagon, and the uncommonly mimicked PYY.

This novel chimeric peptide could deliver up to 30% body weight loss. That effect exceeds the effects of our current crop of weight loss drugs semaglutide and tirzepatide, marketed as Ozempic, Wegovy, and Mounjaro. Semaglutide mimics only GLP1 while tirzepatide mimics both GLP1 and GIP.

This compound is newly discovered and not yet ready for clinical application. When it is, this powerful agent will be an invaluable help for those suffering from excess weight and weight-induced health problems including diabetes, heart disease, and cancer. The hope is that it will quickly move from the laboratory bench into preclinical and clinical trials…..someday soon.

https://www.sciencedaily.com/releases/2025/06/250612081323.htm

https://pubs.acs.org/doi/10.1021/jacs.5c04095

#obesity #semaglutide #tirzepatide #diet #glp1 #gip #glucagon #pyy